Search This Blog

Sunday, August 22, 2021

The mutation that helps Delta spread like wildfire

 As the world grapples with the hyper-infectious Delta coronavirus variant, scientists are racing to understand the biological basis for its behaviour.

A slew of studies has highlighted an amino-acid change present in Delta that might contribute to its swift spread. Delta is at least 40% more transmissible than is the Alpha variant identified in the United Kingdom in late 2020, epidemiological studies suggest.

“The key hallmark of Delta is that transmissibility seems to be ramping up to the next notch,” says Pei-Yong Shi, a virologist at the University of Texas Medical Branch in Galveston. “We thought Alpha was pretty bad, very good at spreading. This one seems to be even more.”

Shi’s team and other groups have zeroed in on a mutation that alters a single amino acid in the SARS-CoV-2 spike protein — the viral molecule responsible for recognizing and invading cells. The change, which is called P681R and transforms a proline residue into an arginine, falls within an intensely studied region of the spike protein called the furin cleavage site.

The presence of this short string of amino acids set off alarm bells when SARS-CoV-2 was first identified in China, because it is associated with heightened infectivity in other viruses such as influenza, but had not previously been found in other sarbecoviruses, the family of coronaviruses to which SARS-CoV-2 belongs. “This little insert sticks out and hits you in the face,” says Gary Whittaker, a virologist at Cornell University in Ithaca, New York.

Pre-activated virus

To penetrate cells, the SARS-CoV-2 spike protein must be cut twice by host proteins. In the SARS-CoV-1 virus that causes severe acute respiratory syndrome (SARS), both incisions occur after the virus has locked on to a cell. But with SARS-CoV-2, the presence of the furin cleavage site means that host enzymes (including one called furin) can make the first cut as newly formed viral particles emerge from an infected cell. These pre-activated viral particles can then go on to infect cells more efficiently than do particles requiring two cuts, says Whittaker.

Delta wasn’t the first SARS-CoV-2 variant to gain a mutation that alters the furin cleavage site. The Alpha variant has a different amino-acid change at the same location as Delta. But the available evidence suggests that the mutation’s effect has been especially profound in Delta.

In a study reported as a preprint on 13 August1, Shi’s team found that the spike protein is cut much more efficiently in Delta-variant particles than in Alpha particles, echoing results reported in May by virologist Wendy Barclay at Imperial College London and her team, who compared Delta with an earlier strain2. Follow-up experiments by both groups showed that the P681R change was largely responsible for spike being clipped so much more efficiently. “This really nailed it, in terms of the mechanism,” says Shi.

Researchers are also beginning to join the dots between P681R and Delta’s ferocious infectivity. Shi’s team found that, in cultured human-airway epithelial cells infected with equal numbers of Delta and Alpha viral particles, Delta rapidly outcompeted the Alpha variant, mimicking epidemiological patterns that have played out globally. But Delta’s advantage disappeared when the researchers eliminated the P681R change.

The mutation might also speed up the spread of SARS-CoV-2 from cell to cell. A team led by Kei Sato, a virologist at the University of Tokyo, found that spike proteins bearing the P681R change fuse with the plasma membranes of uninfected cells — a key step in infection — almost three times faster than do spike proteins lacking the change3.

“I think the virus is succeeding on volume and speed,” says Whittaker. “It’s become a much more efficient virus. It’s going through people and going through cells a lot quicker.”

More than one mutation

Although evidence is building that the P681R change is a crucial feature of Delta, researchers emphasize that it is unlikely to be the only mutation responsible for the variant’s fast spread. Delta carries numerous other mutations to the spike protein, as well as to other less well-studied proteins, that might be important. “It’s very simplistic to say it’s just this 681 change. I think it’s a sum of everything,” says Teresa Aydillo-Gomez, a virologist at Icahn School of Medicine at Mount Sinai in New York City.

Context, both epidemiological and genetic, is also likely to have had a role in Delta’s rise, say scientists. One of Delta’s siblings, a variant called Kappa that, like Delta, was first identified in India, carries many of the same mutations, including P681R, but its effects haven't been as devastating as Delta’s. In a preprint posted on 17 August, a team led by structural biologist Bing Chen at Harvard Medical School in Boston, Massachusetts, reports that Kappa’s spike protein is cleaved less frequently and fuses to cell membranes much less efficiently than does Delta’s4. The researchers say this finding raises questions over the role of P681R.

Researchers in Uganda identified the P681R change in a variant that spread widely in the country in early 2021, but that never took off as Delta did, even though it displays many of the same properties in cell-based lab studies. Whittaker’s team inserted the P681R change into a spike protein from the coronavirus that was circulating in Wuhan, China, at the beginning of the pandemic, and found no increase in its infectivity5. “It takes more than one mutation to make a difference,” he adds.

Regardless of its role in Delta’s dominance, Whittaker and other scientists say, the mutation has underscored the importance of understanding changes in the coronavirus’s furin cleavage site. Whittaker doesn't expect P681R to be the last furin cleavage site mutation to cause concern. “I’m waiting to see what happens next.”

doi: https://doi.org/10.1038/d41586-021-02275-2

https://www.nature.com/articles/d41586-021-02275-2

Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection

 

Ariel IsraelYotam ShenharIlan GreenEugene MerzonAvivit Golan-CohenAlejandro A. SchäfferEytan RuppinShlomo VinkerEli Magen

Comparison of adverse drug reactions among four COVID-19 vaccines

 Maria Abbattista, Ida Martinelli, Flora Peyvandi

DOI:  

https://doi.org/10.1111/jth.15493

PDF: https://onlinelibrary.wiley.com/doi/epdf/10.1111/jth.15493


This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi:10.1111/jth.15493

Summary

Background

Real-world experience with adenoviral vector vaccines against COVID-19 raised some safety concerns. Cases of cerebral vein thrombosis (CVT) associated with thrombocytopenia have been observed after the first dose of the adenoviral vector vaccines CHADOX1 NCOV-19 and AD26.COV2.S.

Objectives

To assess the reporting rate of CVT as adverse drug reaction (ADR) for the COVID-19 vaccines authorized in Europe.

Patients and Methods

This observational study assessed the CVT reporting rate attributed to four COVID-19 vaccines authorized in Europe, namely Tozinameran (Pfizer-Biontech), CX-024414 (Moderna), CHADOX1 NCOV-19 (AstraZeneca) and AD26.COV2.S (Janssen). Data on thrombotic ADRs reported on EudraVigilance database between January 1st, 2021 and July 30th, 2021, were collected. ADRs referring to CVT were identified. The reporting rate of CVT was expressed as 1 million individual vaccinated-days with 95% confidence interval. Finally, an observed-to-expected (OE) analysis was performed.

Results

The reporting rate of CVT per 1 million person vaccinated-days was 1.92 (95% CI, 1.71-2.12) for Tozinameran, 5.63 (95% CI, 4.74-6.64) for CX-024414, 21.60 (95%CI, 20.16-23.11) for CHADOX1 NCOV-19, and 11.48 (95%CI, 9.57-13.67) for AD26.COV2.S. CVT occurred alongside with thrombocytopenia for the four vaccines. The OE ratio was greater than one for all four vaccines, both with the lowest and the highest CVT background incidence.

Conclusions

This report on EudraVigilance data strengthens anecdotal findings on CVT following COVID-19 vaccinations. Although EMA released alert only for CHADOX1 NCOV-19 and AD26.COV2.S, also Tozinameran and CX-024414 are complicated by CVT, albeit to lesser extent.

https://onlinelibrary.wiley.com/doi/10.1111/jth.15493

Therapeutic Solutions to Apply for Emergency Use for Phase 3 COVID-19 Stem Cell Therapy

 Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today initiation of preparation for filing an Emergency Use Authorization (EUA) to the FDA for JadiCells™ in treatment of COVID-19 associated lung injury. 

The EUA is a mechanism that allows FDA to help strengthen the nation’s public health protections against threats such as infectious diseases by facilitating the availability and use of medical countermeasures (MCMs) needed during public health emergencies. Under this provision, the FDA may authorize unapproved medical products to be used in an emergency to treat serious or life-threatening diseases or conditions.

“The extremely promising preclinical data we are generating, as well as the previously published double blind FDA clinical trial and most recently, FDA clearance to enter Phase III, strongly supports the rationale to file for Emergency Use Authorization” said Dr. James Veltmeyer, Chief Medical Officer of the Company. “As a practicing physician, myself and my colleagues are eager to begin using these cells and potentially saving lives”.

In previous studies the Company has demonstrated the superior activity of JadiCell™ to other types of stem cells including bone marrow, adipose, cord blood, and placenta. Furthermore, in an FDA double blind clinical trial the JadiCell™ was shown to be 100% effective in saving the lives of COVID-19 ICU patients1 under the age of 85. On August 5th, 2021, the FDA granted clearance for initiation of a Phase III pivotal trial using JadiCells to treat COVID-192.

https://therapeuticsolutionsint.com/therapeutic-solutions-international-prepares-to-apply-for-emergency-use-authorization-eua-for-its-fda-phase-iii-covid-19-stem-cell-therapy-jadicell/

Cuomo leaves Hochul with staff crisis at Health Department amid COVID

 Disgraced outgoing Gov. Andrew Cuomo is saddling successor Kathy Hochul with a major staffing crisis at the state Health Department when she takes the reins Tuesday, personnel records obtained by The Post reveal.

The records that show 58 DOH employees who made more than $100,000 — including those in top policy positions and scientists tasked with fighting the unrelenting COVID-19 crisis — have fled the agency from Jan. 1 through Aug. 11 this year.

Two more top health officials have submitted resignations since then, bringing the total to 60. One of them is Richard Becker, the governor’s deputy secretary for health and human services who was hired last August.

“Hochul has been handed a depleted and demoralized health department. It’s going to be Hochul’s problem to rebuild DOH,” one former veteran Health Department official told The Post.

“They lost a lot of knowledge and experience and they haven’t replenished it.”

The source said embattled Health Commissioner Howard Zucker was trying to recruit talent to fill vacancies before Cuomo announced his resignation after a devastating investigative report issued by state Attorney General Letitia James on Aug. 3 determined the governor sexually harassed 11 women, including current and former staffers. Cuomo has repeatedly denied those allegations.

August 3 found the governor sexually harassed 11 women, including current and former staffers.

Lieutenant Governor Kathy Hochul
Lieutenant Governor Kathy Hochul will take over as governor of New York on Tuesday.
REUTERS/David 'Dee' Delgado

Cuomo, who faced likely impeachment, announced his resignation after 11 years in office.

The staff exodus and brain drain could complicate Hochul’s decision on whether to dump tarnished Health Commissioner Howard Zucker. He is expected to remain at the helm of the DOH temporarily during Hochul’s 45-day transition and review period.

The list of departures obtained by a Freedom of Information Law request filed with state Comptroller Tom DiNapoli’s office include:

  • Debra Blog, longtime director of the division of epidemiology, the unit responsible for combating communicable diseases and infections like COVID-19 and overseeing immunization programs. Her annual salary was $196,991 when she departed.
  • Victoria Derbyshire, who was deputy director of DOH’s nationally renowned Wadsworth Lab Center for seven years and worked there since 1992. She’s now a health consultant and her LinkedIn page said she spent “the last eight months” as Wadsworth deputy director “in the absence of a director.” She earned $163,688 a year. The Wadsworth director, Jill Taylor, previously resigned.
  • Lauren Tobias, former director of DOH’s Division of Family Health who supported COVID-19 emergency planning efforts. She made $152,000 annually and now works for the lobbying firm Brown & Weinraub.
  • Greg Allen, the former director of program and management who was chiefly responsible for Medicaid services planning and policy. He was paid $188,000.
  • Janet Zachary-Elkind, Allen’s deputy director. She earned $173,000.
  • Peggy Chan, former director of the Office of Health Insurance’s delivery system payment program. She was paid $181,056.
  • Michael Bass, the former $160,690-a-year deputy counsel for litigation.
  • Tracey Fay Raleigh, DOH’s deputy director of the center for planning and licensure.
  • Paula Breen, formerly deputy director of office of professional medical conduct, who made $153,375.
  • Gary Holmes, who earned $168,000 and served as the DOH’s assistant commissioner for communications.
  • Erasmus Schneider, research director and scientists for DOH and its Wadsworth Lab. He was paid $163,860 and retired in June.

Seven other research scientists have also recently left and some of DOH’s managers were transferred to other agencies. Nora Yates, director of DOH’s contract tracing program who previously helped run the center for community health, is now associate commissioner at the state office of children and families.

Hochul’s office did not dispute there’s a staffing problem at DOH.

Dr Howard Zucker
Dr. Howard Zucker will stay on as state Health Commissioner under Kathy Hochul.
Robert Miller

“The Department of Health has thousands of hard working employees across the state, many who continue to work long hours and through difficult circumstances as we battle the COVID-19 pandemic,” said Hochul spokeswoman Haley Viccaro.

“The Lieutenant Governor has outlined a 45-day transition window, and the transition team is actively working to recruit employees both within the Executive Chamber and at all state agencies, including the Department of Health, as part of a new Hochul Administration. We are confident that the government will function at all levels throughout this process,” added Viccaro.

A Health Department spokesperson said the agency has and will continue to “actively recruit” a new generation of employees to steer the agency.

“The Department of Health employees are proud of the role we have played steering New York through an unprecedented pandemic, with many having delayed planned departures or retirement to do so, while others returned from retirement to help manage our COVID-19 response,” said DOH rep Jill Montag.

“We continue to actively recruit the next generation of professionals as we promote the health of New Yorkers and prepare for a new gubernatorial administration in the coming days,” she said.

Many critics have called for Zucker’s ouster for doing Cuomo’s dirty work during the pandemic.

Zucker signed off on the controversial DOH directive during the early days of the pandemic that ordered nursing homes to take in recovering COVID-19 patients from hospitals without prior testing, which critics claimed contributed to the spread of infections and deaths among the elderly in those facilities. Cuomo and Zucker defended the policy, which was later rescinded.

Zucker and DOH also was implicated in Cuomo’s cover up of the true number of COVID-19 deaths in nursing homes and for attempting to absolve the administration of wrongdoing in an in-house report issued last year.

Dr. Howard A. Zucker
Critics have called for Howard Zucker to be ousted for doing Andrew Cuomo’s dirty work during COVID-19.
Michael M. Santiago/Pool via AP

Critics said Cuomo cut out or minimized DOH experts’ role in other key pandemic decisions, such as the rollout of testing and vaccination campaigns.

More than 54,000 people have died of COVID-19 in New York State, according to the Johns Hopkins Coronavirus Resource Center. About 16,000 fatalities were residents in nursing homes and other adult care facilities.

https://nypost.com/2021/08/22/andrew-cuomo-leaves-kathy-hochul-with-staffing-crisis-at-health-dept/

Yellen, Walsh rule out extension of pandemic jobless aid

 Treasury Secretary Janet Yellen and Labor Secretary Marty Walsh said Thursday that the Biden administration will not seek an extension of pandemic jobless aid programs but encouraged states to use funding from the $1.9 trillion stimulus package to support unemployed workers.

In a Thursday letter to congressional leaders, Yellen and Walsh said it is “appropriate” for a $300 weekly boost to unemployment insurance and other expanded benefits programs to expire as scheduled on Sept. 6.

The background: 

  • The March stimulus bill extended the $300 weekly supplement, the Pandemic Unemployment Assistance program for gig workers and contractors and Pandemic Emergency Unemployment Compensation — which provides up to 53 weeks of additional aid — through Labor Day. 
  • Roughly 7.5 million jobless workers will lose all of their unemployment aid after when those programs expire and millions more will receive substantially less without the $300 federal supplement.

“The temporary $300 boost in benefits will expire on September 6th, as planned. As President Biden has said, the boost was always intended to be temporary and it is appropriate for that benefit boost to expire,” Yellen and Walsh wrote to Senate Finance Committee Chairman Ron Wyden (D-Ore.) and House Ways and Means Committee Chairman Richard Neal (D-Mass.).

“In addition, President Biden believes that the conditions exist in many states such that the other emergency UI [unemployment insurance] programs ... can end on the date set in the American Rescue Plan,.”  they continued, referring to the $1.9 trillion stimulus bill Biden signed in March.

The March stimulus bill extended the $300 weekly supplement, the Pandemic Unemployment Assistance program for gig workers and contractors and Pandemic Emergency Unemployment Compensation — which provides up to 53 weeks of additional aid — through Labor Day. 

Roughly 7.5 million jobless workers will lose all of their unemployment aid after when those programs expire and millions more will receive substantially less without the $300 federal supplement.

Yellen and Walsh wrote that the “tremendous progress” of the labor market since March warranted the end of the pandemic unemployment aid nationwide. Twenty-six states, all but one governed by Republicans, have already pulled out of the federal jobless aid programs in a bid to push more residents into available jobs.

Even so, the secretaries acknowledged that some states and cities may still need the expanded federal safety net as the delta variant causes COVID-19 cases to surge and impede the economic recovery.

“There are some states where it may make sense for unemployed workers to continue receiving additional assistance for a longer period of time, allowing residents of those states more time to find a job in areas where unemployment remains high,” they wrote.

Yellen and Walsh encouraged states to use part of their slice of $350 billion in state and local aid included in the March stimulus bill to fund supplements to unemployment benefit amounts, which are determined individually by each state, the District of Columbia, Puerto Rico and the U.S. Virgin Islands.

The Labor Department will also soon release guidelines for how states can incorporate state and local aid into their unemployment systems “to more seamlessly provide support to unemployed workers, while complying with existing federal law and regulations.”

The letter from Yellen and Walsh effectively closes the door on progressives' long-shot hopes for an extension of the jobless aid programs. Even if Biden had backed a bill, it would have likely died in the Senate, where all Republicans and at least one Democrat — Sen. Joe Manchin (W.Va.) — would oppose it.

Advocates for expanded unemployment aid say that while the economy may be improving, the pandemic illustrated the need for wide-scale improvements to the federal aid system. Dozens of state unemployment offices run through antiquated computed systems crumbled under the rush of applications, including several fraud schemes that likely sucked up millions of dollars.

“Beyond the immediate issue of expiring benefits, President Biden believes that the pandemic has exposed serious problems in our UI system that require immediate reform. Accordingly, he is calling on Congress to take up the issue of long-term UI reform as part of the reconciliation process, when Congress returns from recess,” Yellen and Walsh wrote.

In a statement responding to the letter, Wyden touted the success of the stimulus bill and praised the Biden administration for backing major reforms to jobless aid, one of his top priorities. 

“If we finally bring unemployment insurance into the 21st century, there won’t be the same drastic need to temporarily patch the system in midst of the next recession,” Wyden said. 

https://thehill.com/policy/finance/568617-yellen-walsh-rule-out-extension-of-pandemic-jobless-aid


COVID-19 vaccine effectiveness down against new infections in NY

 Currently available vaccines are effective for preventing severe acute respiratory syndrome coronavirus-2 infection and COVID-19-associated hospitalization, but vaccine effectiveness has declined in recent months in New York, according to research published in the Aug. 18 early-release issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Eli S. Rosenberg, Ph.D., from the New York State Department of Health in Albany, and colleagues linked statewide immunization, laboratory testing, and hospitalization databases for New York to estimate the rates of new laboratory-confirmed COVID-19 cases and hospitalizations by vaccination status among adults having received one of the three vaccines the U.S. Food and Drug Administration has authorized for emergency use.

The researchers found that the overall age-adjusted vaccine effectiveness against new COVID-19 cases for all adults decreased from 91.9 to 79.8 percent during May 3 to July 25, 2021. The overall age-adjusted  against hospitalization was relatively stable during the same period, ranging from 91.9 to 95.3 percent.

"Vaccine effectiveness against infection appears to have declined in recent months in New York, coinciding with a period of easing societal public health restrictions and increasing delta variant circulation," the authors write. "These findings support a multipronged approach to reducing new COVID-19 hospitalizations and cases, centered on vaccination, and including other approaches such as masking and physical distancing."


Explore further

COVID-19 vaccines effectively prevent hospitalization for seniors

More information: Abstract/Full Text
https://medicalxpress.com/news/2021-08-covid-vaccine-effectiveness-infections-york.html